Sanofi lays out regulatory schedule for Lemtrada; Keryx out to raise $55M; New MS target;

 @FierceBiotech: From FierceBiotechIT.com: Cypher Genomics chief speaks out from DNA data-crunching crowd. News | Follow @FierceBiotech

@JohnCFierce: Are we in for a string of winning biotech IPOs? Been a long time: First biotech IPO of '13 jumps in encouraging debut. More | Follow @JohnCFierce

@RyanMFierce: Is Pfizer stronger long-term without generics or just temporarily satisfying Wall Street? Report | Follow @RyanMFierce

> Sanofi ($SNY) says it plans to hear back from the FDA on its decision regarding the MS drug Lemtrada in the second half of this year. Experts at the EMA are expected to weigh in during the second quarter. Story

> Bolstered by upbeat data on Zerenex, Keryx is looking to raise $55 million from a new public offering. Report

Pharma News

@FiercePharma: Vertex numbers suffer from Incivek sales swoon. Hep C drug down 51%. Whoa. Fewer new pts. More | Follow @FiercePharma

 @AlisonBFierce: Life established an international flu network to up the speed and efficiency of flu monitoring and vaccine development. Release | Follow @AlisonBFierce

@EricPFierce: The world's largest OTC plant gets under way. More | Follow @EricPFierce

> France yanking Bayer's Diane-35 off the market. Article

> Pfizer may split, CEO says, but don't expect a decision soon. Story

Medical Device News

 @FierceMedDev: In case you missed it... The top medical device venture capital investments of 2012. Special Report | Follow @FierceMedDev

 @MarkHFierce: This just in: Boston Scientific's CEO says the medical device tax, in part, is forcing up to 1,000 more layoffs. Article | Follow @MarkHFierce

 @DamianFierce: Medtronic ups the ante in China, buying a $66.2M stake in a Shenzhen cardiovascular biz. More | Follow @DamianFierce

> St. Jude study targets broader renal denervation use. Report

> Autism blood Dx might focus on fat metabolism marker. News

> Roche Diagnostics leaps 4% in 2012, snags 20% market share. Story

Drug Delivery News

> Sanofi launches 'talking' emergency epinephrine injector. Report

> Sustained-release contact lenses deliver eye drugs post-surgery. Article

> DNA vaccine tattoo triggers HIV immune response. News

> MIT researchers deliver to cells with a squeeze. Story

> Tunable jelly takes ups and downs out of peptide delivery. Item

And Finally… Investigators at Boston University School of Medicine say that the protein Klotho plays a big role in maintaining healthy myelin, making it a potential target for MS researchers as well as Alzheimer's disease. Release

 

Suggested Articles

Disarm Therapeutics signed on Alvin Shih, M.D., the former Retrophin R&D chief who went on to helm Enzyvant, as its full-time CEO.

Pact Pharma launched a phase 1 trial of a technology designed to attack solid tumors with CAR-T cells tailored to individual patients.

Intec's candidate uses a drug delivery system designed to improve on Merck’s Sinemet but was unable to beat the product in a late-phase test.